Faculty Articles
Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women
Publication Title
P&T (Pharmacy & Therapeutics)
Publisher
MediMedia
Publication Date
4-1-2017
Keywords
arousal, females, hypoactive sexual desire disorder (HSDD), menopause, pre-menopause, sexual interest
Abstract
Female sexual interest/arousal disorder (FSIAD) is a newly defined clinical diagnosis that appears in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5).1 The diagnosis was previously listed as hypoactive sexual desire disorder (HSDD) in DSM-4 and as inhibited sexual desire disorder in DSM-3. References to the condition prior to 2013 (and even afterward), including research studies, often refer to the condition as HSDD.
Volume
42
Issue
4
First Page
237
Last Page
241
Disciplines
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
NSUWorks Citation
English, Clayton; Muhleisen, Anne; and Rey, Jose A., "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women" (2017). Faculty Articles. 334.
https://nsuworks.nova.edu/hpd_corx_facarticles/334
